MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

Patients with end stage renal disease (ESRD) who use peritoneal dialyses with Physioneal(R) (Baxter A/S, Denmark) were allocated to inject either placebo or tinzaparin daily into the morning dialysis bag. Active medication, as well as placebo, was added for three months separated by a one month washout period. At the beginning and end of each treatment period peritoneal equilibrations tests (PE-tests), Kt/V, blood and dialysate samples were analyzed. We, the researchers at Ribe County Hospital, set out to examine inflammation (local and systemic), nutrition and ultrafiltration.

Inclusion Criteria:

• End stage renal disease
• Peritoneal dialysis without complication for minimum of three months
• 18 years or above
• Informed consent

Exclusion Criteria:

• Known coagulatory defects including anticoagulation therapy
• Known bleeding tendency
• Peritonitis within two months prior to inclusion
• Pregnancy
• Breast feeding
• Active infection
• Non-informed consent
• Allergy to heparin or prior heparin induced thrombocytopenia